GSK PHARMA | ISTREET NETWORK | GSK PHARMA/ ISTREET NETWORK |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 60.6 | -49.7 | - | View Chart |
P/BV | x | 22.9 | - | - | View Chart |
Dividend Yield | % | 1.3 | 0.0 | - |
GSK PHARMA ISTREET NETWORK |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GSK PHARMA Mar-24 |
ISTREET NETWORK Mar-24 |
GSK PHARMA/ ISTREET NETWORK |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,650 | 3 | 82,296.6% | |
Low | Rs | 1,228 | 1 | 87,092.2% | |
Sales per share (Unadj.) | Rs | 203.9 | 0 | - | |
Earnings per share (Unadj.) | Rs | 34.8 | -0.1 | -57,500.8% | |
Cash flow per share (Unadj.) | Rs | 38.9 | -0.1 | -64,292.2% | |
Dividends per share (Unadj.) | Rs | 32.00 | 0 | - | |
Avg Dividend yield | % | 1.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 105.5 | -0.8 | -12,734.5% | |
Shares outstanding (eoy) | m | 169.41 | 21.30 | 795.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 9.5 | 0 | - | |
Avg P/E ratio | x | 55.7 | -38.2 | -145.9% | |
P/CF ratio (eoy) | x | 49.8 | -38.2 | -130.5% | |
Price / Book Value ratio | x | 18.4 | -2.8 | -657.7% | |
Dividend payout | % | 91.9 | 0 | - | |
Avg Mkt Cap | Rs m | 328,474 | 49 | 666,140.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 6,244 | 0 | 2,014,161.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 34,537 | 0 | - | |
Other income | Rs m | 1,226 | 0 | 12,259,400.0% | |
Total revenues | Rs m | 35,763 | 0 | 357,630,000.0% | |
Gross profit | Rs m | 7,651 | -1 | -588,517.7% | |
Depreciation | Rs m | 697 | 0 | - | |
Interest | Rs m | 18 | 0 | - | |
Profit before tax | Rs m | 8,162 | -1 | -632,703.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,262 | 0 | - | |
Profit after tax | Rs m | 5,900 | -1 | -457,334.1% | |
Gross profit margin | % | 22.2 | 0 | - | |
Effective tax rate | % | 27.7 | 0 | - | |
Net profit margin | % | 17.1 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,984 | 1 | 2,120,014.4% | |
Current liabilities | Rs m | 15,249 | 2 | 847,192.2% | |
Net working cap to sales | % | 36.9 | 0 | - | |
Current ratio | x | 1.8 | 0.7 | 250.2% | |
Inventory Days | Days | 115 | 0 | - | |
Debtors Days | Days | 235 | 0 | - | |
Net fixed assets | Rs m | 6,119 | 1 | 737,213.3% | |
Share capital | Rs m | 1,694 | 85 | 1,988.3% | |
"Free" reserves | Rs m | 16,172 | -103 | -15,725.8% | |
Net worth | Rs m | 17,866 | -18 | -101,283.7% | |
Long term debt | Rs m | 0 | 18 | 0.0% | |
Total assets | Rs m | 34,103 | 2 | 1,578,844.9% | |
Interest coverage | x | 454.7 | 0 | - | |
Debt to equity ratio | x | 0 | -1.0 | -0.0% | |
Sales to assets ratio | x | 1.0 | 0 | - | |
Return on assets | % | 17.4 | -59.8 | -29.0% | |
Return on equity | % | 33.0 | 7.3 | 450.8% | |
Return on capital | % | 45.8 | -358.9 | -12.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 22.9 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 7,912 | NA | - | |
Fx inflow | Rs m | 1,342 | 0 | - | |
Fx outflow | Rs m | 7,912 | 0 | - | |
Net fx | Rs m | -6,570 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 5,820 | -1 | -554,301.0% | |
From Investments | Rs m | 87 | NA | 871,200.0% | |
From Financial Activity | Rs m | -5,615 | NA | - | |
Net Cashflow | Rs m | 292 | -1 | -28,105.8% |
Indian Promoters | % | 0.0 | 46.2 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 11.7 | 0.0 | - | |
FIIs | % | 4.4 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.0 | 53.8 | 46.5% | |
Shareholders | 119,228 | 11,450 | 1,041.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GSK PHARMA With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | GSK Pharma | PRINCIPAL PHARMA | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.86% | 0.00% | 1.23% |
1-Month | -6.46% | -7.35% | -0.24% |
1-Year | 42.64% | 30.71% | 43.62% |
3-Year CAGR | 14.79% | 10.10% | 20.35% |
5-Year CAGR | 8.09% | 9.08% | 26.24% |
* Compound Annual Growth Rate
Here are more details on the GSK Pharma share price and the PRINCIPAL PHARMA share price.
Moving on to shareholding structures...
The promoters of GSK Pharma hold a 75.0% stake in the company. In case of PRINCIPAL PHARMA the stake stands at 46.2%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of GSK Pharma and the shareholding pattern of PRINCIPAL PHARMA.
Finally, a word on dividends...
In the most recent financial year, GSK Pharma paid a dividend of Rs 32.0 per share. This amounted to a Dividend Payout ratio of 91.9%.
PRINCIPAL PHARMA paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of GSK Pharma, and the dividend history of PRINCIPAL PHARMA.
For a sector overview, read our pharmaceuticals sector report.
After opening the day higher, Indian benchmark indices remained positive as the session progressed and ended the day on firm footing.